Tvardi Therapeutics (NASDAQ: TVRD) files Q2 2025 results 8-K report

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. filed a Form 8-K to furnish a press release announcing its financial results for the fiscal quarter ended June 30, 2025. The company, formerly known as Cara Therapeutics, issued the release on August 14, 2025, and attached it as Exhibit 99.1.

The disclosure is provided under Item 2.02, "Results of Operations and Financial Condition," and is expressly described as being "furnished" rather than "filed," which limits its applicability for certain securities law liability provisions and for automatic incorporation by reference into other SEC filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001346830 0001346830 2025-08-14 2025-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) August 14, 2025

TVARDI THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36279		75-3175693
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)
3 Sugar Creek Ctr. Blvd. Suite 525 Sugar Land, Texas				77478
(Address of principal executive offices)				(Zip Code)

Registrant's telephone number, including area code: (713) 489-8654

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TVRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On August 14, 2025, Tvardi Therapeutics, Inc. (formerly Cara Therapeutics, Inc.) (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended June 30, 2025. A copy of the Company’s press release dated August 14, 2025 is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information contained herein and the accompanying Exhibit 99.1 is being furnished under “Item 2.02 Results of Operations and Financial Condition” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended, nor shall it be deemed incorporated by reference in any filing with the Securities and Exchange Commission made by us, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press release issued on August 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	TVARDI THERAPEUTICS, INC.
Date: August 14, 2025	By:	/s/ Imran Alibhai
	Name:	Imran Alibhai
	Title:	Chief Executive Officer

FAQ

What did Tvardi Therapeutics (TVRD) report in this Form 8-K?

Tvardi Therapeutics, Inc. furnished a press release announcing its financial results for the fiscal quarter ended June 30, 2025 under Item 2.02 of Form 8-K.

Which period do the Tvardi Therapeutics (TVRD) results cover?

The financial results discussed relate to Tvardi Therapeutics, Inc.’s fiscal quarter ended June 30, 2025.

What is Exhibit 99.1 in the Tvardi Therapeutics (TVRD) Form 8-K?

Exhibit 99.1 is the press release issued on August 14, 2025, in which Tvardi Therapeutics, Inc. announces its quarterly financial results.

Is the Tvardi Therapeutics (TVRD) earnings information considered filed or furnished?

The earnings information and Exhibit 99.1 are being furnished under Item 2.02 and are not deemed filed for purposes of Section 18 of the Exchange Act or Sections 11 and 12(a)(2) of the Securities Act.

Does this Tvardi Therapeutics (TVRD) Form 8-K include detailed financial statements?

The Form 8-K itself refers to a press release containing the financial results, attached as Exhibit 99.1, rather than providing detailed financial statements within the body of the report.

Who signed the Tvardi Therapeutics (TVRD) Form 8-K?

The Form 8-K was signed on behalf of Tvardi Therapeutics, Inc. by Imran Alibhai, the company’s Chief Executive Officer.